RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa

Scientific Reports
Lucas Milanez BenicioMarcelo Tempesta De Oliveira

Abstract

The present study tested the effects of a newly identified indolin-3-one compound (compound 1), produced by Pseudomonas aeruginosa, on HepG2 cells. The MTT assays demonstrated decreased metabolic activities in HepG2 cells treated with compound 1, with dose- and time-dependent intensifying effect, starting at a concentration of 40 µM. The IC50 after 24, 48, 72, and 96 h treatments were 41.35, 52.7, 92.79 and 66.65 μM of compound 1, respectively. Below 80 µM, no significative damage on erythrocytes membranes was observed by the hemolytic assays. The RT-qPCR revealed that the compound modulated key genes involved in carcinogenesis process, indicating possible indolin-3-one mechanisms of action. The data showed that gene expression alterations promoted by compound 1, in concentrations up to 60 μM after 48 h, led to a decrease in cellular progression and there was no direct cellular damage. In addition, non-cytotoxic concentrations of compound 1 halved the concentration of the chemotherapeutic doxorubicin, maintaining similar therapeutic effect against HepG2 cells. The novelty of the molecule and the biological activities observed in the present study emphasize the potential of the compound 1 in cancer therapy research.

References

Jul 4, 2001·Nature Cell Biology·P M Comoglio
Jun 28, 2002·Cancer Cell·Laura K ShawverAxel Ullrich
Sep 19, 2002·Trends in Pharmacological Sciences·Marie KnockaertLaurent Meijer
Jun 20, 2003·Cell Proliferation·Katrien VermeulenZwi N Berneman
Sep 21, 2006·Molecular Cancer Therapeutics·Giuliana CassinelliFranco Zunino
Apr 18, 2008·Environmental and Molecular Mutagenesis·Irena HreljacMetka Filipic
Sep 25, 2008·Nature Reviews. Molecular Cell Biology·Helfrid HocheggerTim Hunt
Dec 23, 2008·Cancer Letters·Christine M Stellrecht, Varsha Gandhi
Feb 25, 2009·Nucleic Acids Research·J M RuijterA F M Moorman
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 2, 2011·International Journal of Pharmaceutics·Regina Scherliess
Oct 25, 2011·European Journal of Medicinal Chemistry·Hongbin ZouYongping Yu
Jan 10, 2012·Electrophoresis·Patrick S ArandaCheryl L Jorcyk
Apr 5, 2012·Critical Reviews in Oncogenesis·Andrew StoneElizabeth A Musgrove
Apr 25, 2012·Annual Review of Analytical Chemistry·Sara A LoveChristy L Haynes
Sep 15, 2012·Methods : a Companion to Methods in Enzymology·Jan M RuijterJo Vandesompele
Apr 9, 2013·Journal of Natural Medicines·Alfarius Eko Nugroho, Hiroshi Morita
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Nov 13, 2015·Expert Opinion on Therapeutic Patents·Alberto LeoniMirella Rambaldi
Oct 5, 2016·Current Topics in Medicinal Chemistry·Dhanya Sunil, Pooja R Kamath
Oct 5, 2016·Recent Patents on Anti-cancer Drug Discovery·Anuj K RathiRahul V Patel

❮ Previous
Next ❯

Citations

Mar 27, 2020·Chemical Communications : Chem Comm·Yu-Hsuan ChangYen-Ku Wu
Jan 9, 2021·Microbiology Resource Announcements·Ane Stéfano SimionatoGaldino Andrade

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
circular dichroism
electrophoresis

Software Mentioned

R
Gaussian
REST®
LinRegPCR
REST
CFX Manager
GraphPad Prism

Related Concepts

Related Feeds

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.